The fact that CHF03 supplementation decreased abundance of NF-κB in vivo and also in PA-stimulated AML12 cells suggests that the protective effect on NAFLD is related to its ability to regulate NF-κB signaling and inhibit inflammation. This evidence concerns the gene NFKB1 and metabolic dysfunction-associated steatotic liver disease.